NDT Pharmaceuticals, Inc. engages in the business of developing nutraceutical and pharmaceutical products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-12-14. The firm has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes an applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine. The NPC technology also incorporates a potent active ingredient that stimulates the repair of damaged cell tissue branded by the Company as Cell Armor.
Follow-Up Questions
NDT Pharmaceuticals Inc의 CEO는 누구입니까?
Kent Carasquero은 2007부터 회사에 합류한 NDT Pharmaceuticals Inc의 Chief Executive Officer입니다.
NDTP 주식의 가격 성능은 어떻습니까?
NDTP의 현재 가격은 $1.18이며, 전 거래일에 decreased 0% 하였습니다.
NDT Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
NDT Pharmaceuticals Inc은 Metals & Mining 업종에 속하며, 해당 부문은 Materials입니다
